Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the U.S.

Bellicum today announced that the Company has received notice from the FDA that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.